PDL BioPharma Inc. (PDLI) announced that it has entered into a non-exclusive license agreement with Eli Lilly and Co (LLY) under PDL's Queen et al patents with respect to teplizumab, as well as other potential next generation anti-CD3 molecules.
Teplizumab is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus.
Lilly currently holds a license to the Queen et al patents with respect to solanezumab.
For comments and feedback: editorial@rttnews.com